Efficacy and safety of RC48 in combination with PD-1 inhibitors for the treatment of locally advanced or metastatic urothelial carcinoma: a single-center, real-world study
The combination of RC48 and PD-1 inhibitors exhibits promising antitumor activity and a manageable safety profile in patients with locally advanced or metastatic UC.
Authors
- Mengting Shi (ORCID: https://orcid.org/0009-0007-0847-0145)
- Tao Lu (ORCID: https://orcid.org/0000-0002-8247-8387)
- Yuanyuan Guo (ORCID: https://orcid.org/0000-0002-3042-8417)
- Yue Wu (ORCID: https://orcid.org/0000-0002-7349-959X)
- Tiantian Zhang (ORCID: https://orcid.org/0000-0003-4076-8463)
- Rui Wang (ORCID: https://orcid.org/0000-0003-3847-5821)
- Shuo He (ORCID: https://orcid.org/0009-0006-6192-4946)
Institutions
- Bengbu Medical College (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1007/s12672-025-02362-0
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02